C
Coherent Biopharma (Suzhou)
Bi-specific ligand-drug conjugates for targeted oncology therapeutics
About Coherent Biopharma (Suzhou)
Coherent Biopharma (Suzhou) Co. Ltd. is a clinical-stage biopharmaceutical company founded in 2016 by Dr. Baohua (Robert) Huang. The company focuses on the research, development, and commercialization of bi-targeting ligand-drug conjugate (Bi-XDC) drugs for oncology and other chronic diseases. Dr. Huang, who serves as Chairman and CEO, is a serial entrepreneur with over 30 years of experience in the pharmaceutical and biotech industries, having held roles at major companies like Abbott Labs and Amgen (Tularik). He holds a PhD in Biochemistry from The Ohio State University, an MBA from Cornell University, and has authored numerous scientific papers and patents.
Coherent Biopharma's core technology is its proprietary Bi-XDC platform, which is designed to empower molecules that were previously considered undruggable. This technology is distinct from antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs), aiming to offer a better therapeutic window, improved plasma stability, and more targeted drug enrichment in tumors. The platform includes several components like the BEST™ Platform and the C-PROTAC Platform, which enable the specific delivery of bioactive molecules to diseased tissues. The business model centers on advancing its pipeline of drug candidates through clinical trials to address unmet medical needs in cancer treatment. The company operates globally with a management organization across China, the U.S., and Australia.
The company's pipeline includes several candidates in various stages of clinical development. Its lead asset, CBP-1008, is a bispecific conjugate targeting FRα and TRPV6 for cancers such as platinum-resistant ovarian cancer and triple-negative breast cancer. CBP-1018 targets PSMA and is being studied for metastatic castration-resistant prostate cancer (mCRPC). Another key candidate, CBP-1019, is a next-generation conjugate for solid malignancies like endometrial, colorectal, and pancreatic cancer. The company has received Fast Track Designation from the U.S. FDA for both CBP-1008 and CBP-1019, expediting their development and review process. Coherent Biopharma has secured significant funding to advance its clinical trials, including raising $100 million in Series B and B+ financing rounds in 2023.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | May 2023 | $100M | $400M | Shanghai Lianhe Investment · Suzhou Industrial Park Science and Technology Innovation Fund · Hefei Hi-Tech Venture Capital · Hefei Industry Investment Group | ↗ |
| SERIES BOther financing | Jul 2022 | $0 | — | HM Capital · YunFeng Capital · ABC International Holdings | ↗ |
Growth signals
Latest recorded traffic for Coherent Biopharma (Suzhou) is 410 monthly website visits, down 82.9% over the last three months. Coherent Biopharma (Suzhou)'s team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Coherent Biopharma (Suzhou) in its local ecosystem
The Coherent Biopharma (Suzhou) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
- FBFrontline BioVentures
6 Dimensions Capital
HM Capital
YunFeng Capital
ABC International Holdings- SIShanghai Lianhe Investment
- SFSuzhou Industrial Park Science and Technology Innovation Fund
- HCHefei Hi-Tech Venture Capital
- HGHefei Industry Investment Group
- LCLeading Venture Capital
Shengdi Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Coherent Biopharma (Suzhou) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Coherent Biopharma (Suzhou)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










